Professor Dyfrig Hughes

Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil

Affiliations

North Wales Medical School

Links

http://cheme.bangor.ac.uk

ORCID: 0000-0001-8247-7459

376 - 400 out of 446Page size: 25

Sort by: Type

Poster › Research › Peer-reviewed
Published

Patient-level information and costing systems (PLICS) as a source of routinely collected cost data for trial-based economic evaluations
Ridyard, C. & Hughes, D., 7 May 2017, p. P141. 1 p.
Research output: Contribution to conference › Poster › peer-review
Abstract › Research › Peer-reviewed
Published

Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)
Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Sept 2017, p. 22-23.
Research output: Contribution to conference › Abstract › peer-review
Other › Research › Peer-reviewed
Published

Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa
Culeddu, G., Brogan, P. A. & Hughes, D., 2021.
Research output: Contribution to conference › Other › peer-review
Commissioned report › Research › Not peer-reviewed
Published

A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.
Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

AWMSG criteria for appraising new medicines.
Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report
Published

All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.
Research output: Book/Report › Commissioned report

Previous 1...12 13 14 15 16 17 18 Next